Avacopan new focus for VFMCRP and ChemoCentryx, CCX140 won’t move forward in FSGS
In the study, CCX140 did not demonstrate a meaningful reduction in proteinuria relative to the control group after 12 weeks of blinded treatment.
Pharmaceuticals, Biotechnology and Life Sciences
In the study, CCX140 did not demonstrate a meaningful reduction in proteinuria relative to the control group after 12 weeks of blinded treatment.
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create…
IMV is preparing to advance a DPX-based vaccine candidate for COVID-19, which is on track to enter into clinical trials later this summer.
CanFite is working on Piclidenoson’s anti-viral, anti-inflammatory, anti-rheumatic properties and excellent safety profile make it a strong candidate for the…
Stoke Therapeutics is on track to begin enrollment and dosing of STK-001 in Part A of Phase 1/2a “Monarch” clinical trial in children and adolescents with Dravet syndrome in 2H 2020.
The company reported a net loss of $8.2 million, or $0.47 per share, for the three months ended March 31, 2020, compared to a net loss of $4.9 million, or $0.52 per share, for the same period in 2019. The company had $11.8 million in cash and cash equivalents as of March 31, 2020.
Avacta said that Affimer reagents recently generated for development of a point-of-care COVID-19 antigen saliva test have now also been shown to block the interaction between the virus’ spike protein and ACE2, a receptor on human cells that is key to the virus infection pathway.
T G4050 is being evaluated in two Phase 1 clinical trials. It combines Transgene’s proprietary myvac® platform with NEC’s cutting-edge…
These data support the potential of our HPK1 inhibitor to alter the tumor microenvironment to halt cancer’s immune evasion, which we think could be a powerful tool in today’s immuno-oncology arsenal.
Arctic Vision, a clinical stage biotechnology company focusing on the development and commercialization of innovative ophthalmology therapies in China and Asia, announced today the formation of its Scientific Advisory Board (SAB) comprised of three world-class ophthalmologists from China, the United States and the United Kingdom.